NCT06031454

Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin

A Open-Label, Two-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of Leritrelvir With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Guangdong Raynovent Biotech Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The drug-drug interaction study had been designed to investigate the effect of Leritrelvir on the pharmacokinetics of Midazolam, Omeprazole, Rosuvastatin and the effect of Verapamil and Rifampin on the pharmacokinetics of Leritrelvir

Conditions

• Drug Drug Interaction

Interventions

Type	Name	Description
DRUG	Midazolam	oral
DRUG	Omeprazole	oral
DRUG	Rosuvastatin	oral
DRUG	Verapamil	oral
DRUG	Rifampin	oral
DRUG	Leritrelvir	oral

Timeline

• Start date: 2023-09-01
• Primary completion: 2023-11-01
• Completion: 2023-12-31
• First posted: 2023-09-11
• Last updated: 2024-04-16

Locations

1 site across 1 country: China